Sparks commentary - Oryzon Genomics

Healthcare

Sparks - Oryzon Genomics

More on this equity
Oryzon (BME: ORY) publishes results of vafidemstat in PMS
Published by Arron Aatkar, PhD

Oryzon Genomics has announced the publication of a study in Frontiers in Psychiatry, which explores the potential of vafidemstat in Phelan-McDermid Syndrome (PMS). PMS is a form of autism whereby agitation and aggression (A/A) are key traits. It is therefore logical to consider vafidemstat in this patient population, given that it is being evaluated to address borderline personality disorder in later-stage clinical development, a condition also characterised by A/A.

This PMS study was observational, designed to psychometrically characterise PMS patients carrying deletions or pathogenic variants in the SHANK3 gene. It is intended that the data gathered in this study could be used as a foundation for a subsequent precision psychiatry clinical trial involving vafidemstat in this population, potentially bolstering the value proposition for the candidate.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free